ARDS
Aridis Pharmaceuticals Inc
Halal Rating :
Last Price
$0.00
Last updated:
Market Cap
-
7D Change
-100.0%
1 Year Change
-100.0%
Company Overview
Industries
Exchange
Next Earnings Date
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing novel anti-infective therapies to treat life-threatening infections. The company's primary focus is on developing monoclonal antibodies for the treatment of bacterial infections, particularly those that are resistant to current antibiotics.
The company's pipeline includes AR-301 (salvecin), AR-501 (panaecin), AR-712, and AR-320 (AR-101). These candidates target infections such as pneumonia and other respiratory tract infections.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $417000.0 | $1.29m | - | - | 0.00% | 0.00% |
| June 30, 2023 | $19.65m | $5.98m | - | - | 0.00% | 0.00% |
| March 31, 2023 | $1.08m | $7.34m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Aridis Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.